Health Ministry Proposes Separate Licensing Rules for Bulk Drug Wholesalers in India
News Synopsis
The Health Ministry has proposed separate licences for bulk drug wholesalers to strengthen pharmaceutical regulation, improve supply chain monitoring and enhance accountability across India's drug distribution network.
Health Ministry Proposes Separate Licensing Framework for Bulk Drugs
The Union Ministry of Health and Family Welfare has proposed significant changes to the Drugs Rules, 1945, to introduce a dedicated licensing system for the wholesale distribution of bulk drugs in India.
The proposal, published through Draft Gazette Notification G.S.R. No. 987 (E) dated November 2, 2026, aims to establish separate regulatory requirements for wholesalers dealing in active and inactive pharmaceutical ingredients.
Under the proposed changes, bulk drug distributors will need to obtain a dedicated licence instead of operating under the existing common licensing arrangement for pharmaceutical formulations and bulk drugs.
New Application and Licence Forms for Bulk Drug Wholesalers
The draft amendments propose introducing two new forms to regulate bulk drug wholesale activities.
-
Form 19-BC: A separate application form that wholesalers will use to apply for a bulk drug licence.
-
Form 20-BC: The proposed licence document that will authorise businesses to undertake wholesale distribution of bulk drugs.
Currently, wholesalers can distribute both pharmaceutical formulations and bulk drugs under a common licence. The proposed system aims to separate these activities and establish more focused regulatory supervision.
The government believes that a dedicated licensing structure will improve accountability and make it easier for authorities to monitor the movement and distribution of pharmaceutical ingredients.
Regulatory Approval From DCC and DTAB
The proposed changes have received recommendations from two important regulatory bodies responsible for advising the government on pharmaceutical standards and drug regulation.
The Drugs Consultative Committee (DCC) approved the proposal during its 67th meeting held on November 17, 2025.
Subsequently, the Drugs Technical Advisory Board (DTAB) considered and approved the proposal at its 93rd meeting on February 16, 2026.
These recommendations have contributed to the development of the draft amendments, which are now open for public and stakeholder feedback.
Bulk Drug Licences to Include Specific Drug Categories
Under the proposed framework, licences will clearly mention the categories of bulk drugs that a wholesaler is authorised to handle.
This will also cover substances regulated under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985.
The provision is expected to improve monitoring of controlled pharmaceutical substances and provide regulatory authorities with better information about their distribution.
Another important requirement is that wholesale transactions involving bulk drugs must take place under the personal supervision of a competent person.
This condition is intended to strengthen professional oversight and ensure that bulk drug distribution follows the applicable regulatory requirements.
Why the Government Wants Separate Bulk Drug Licensing
The proposed amendments are aimed at improving transparency, accountability and regulatory control throughout India's pharmaceutical supply chain.
1. Stronger Monitoring of Drug Distribution
Separate licences will help authorities identify wholesalers dealing specifically in bulk drugs and monitor their business activities more effectively.
2. Better Control Over Antimicrobial Resistance
The government intends to strengthen enforcement measures associated with antimicrobial resistance (AMR). Better oversight of bulk drug distribution can support efforts to monitor the movement and handling of pharmaceutical substances.
3. Monitoring Drugs Covered Under the NDPS Act
The proposed framework will improve supervision of bulk substances regulated under the NDPS Act, helping authorities monitor their distribution and prevent regulatory violations.
4. Greater Accountability Among Wholesalers
Mandatory separate licensing will establish clearer responsibilities for businesses involved in bulk drug distribution and make regulatory inspections more focused.
Existing Licensees to Receive Additional Compliance Time
The government has proposed transitional arrangements to ensure that businesses already operating under the current licensing system are not required to make immediate changes.
Existing licence holders will receive adequate time to meet the revised requirements.
The new provisions will become applicable to existing licensees after the expiry of their current licence retention period or 12 months from the final publication of the amendment, whichever occurs later.
This arrangement is intended to give wholesalers sufficient time to complete the necessary documentation and obtain the new licence without disrupting their business operations.
Health Ministry Invites Public Objections and Suggestions
The Ministry of Health and Family Welfare has invited feedback from stakeholders, pharmaceutical businesses and members of the public regarding the proposed amendments.
Interested parties can submit their objections and suggestions within 30 days from the date on which copies of the Gazette notification containing the draft rules are made available to the public.
Submission details:
-
Address: Under Secretary (Drugs), Ministry of Health and Family Welfare, Government of India, U-6, Work Hall, C Wing, First Floor, Kartavya Bhawan-1, New Delhi–110001.
-
Email: drugsdiv-mohfw@gov.in
-
Subject: Objections and suggestions regarding the proposed amendments to the Drugs Rules, 1945.
The feedback received during this period will help the government consider stakeholder concerns before finalising the amendments.
Conclusion: New Licensing Rules Aim to Strengthen India's Pharmaceutical Supply Chain
The proposed separate licensing framework represents an important step towards improving the regulation of bulk drug distribution in India.
By introducing dedicated application and licence forms, specifying drug categories and strengthening supervision, the government aims to improve transparency and accountability across the pharmaceutical supply chain.
The proposed measures could also support better monitoring of controlled substances and strengthen efforts to address antimicrobial resistance. Once finalised, the amendments will establish clearer compliance requirements for bulk drug wholesalers across the country.
You May Like


